The stock of Shire PLC (ADR) (NASDAQ:SHPG) is a huge mover today! About 519,117 shares traded hands. Shire PLC (ADR) (NASDAQ:SHPG) has risen 18.02% since March 11, 2016 and is uptrending. It has outperformed by 12.56% the S&P500.
The move comes after 7 months negative chart setup for the $57.41B company. It was reported on Oct, 14 by Barchart.com. We have $177.67 PT which if reached, will make NASDAQ:SHPG worth $3.44B less.
Analysts await Shire PLC (ADR) (NASDAQ:SHPG) to report earnings on October, 28. They expect $3.14 EPS, down 3.09% or $0.10 from last year’s $3.24 per share. SHPG’s profit will be $953.75M for 15.05 P/E if the $3.14 EPS becomes a reality. After $3.38 actual EPS reported by Shire PLC (ADR) for the previous quarter, Wall Street now forecasts -7.10% negative EPS growth.
Shire PLC (ADR) (NASDAQ:SHPG) Ratings Coverage
Out of 18 analysts covering Shire plc (ADR) (NASDAQ:SHPG), 15 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 83% are positive. Shire plc (ADR) has been the topic of 28 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Tuesday, June 28 by Goldman Sachs. The firm earned “Neutral” rating on Thursday, August 6 by BNP Paribas. The company was initiated on Friday, May 6 by Liberum Capital. The company was upgraded on Tuesday, November 17 by Leerink Swann. The firm has “Hold” rating by HSBC given on Monday, September 26. Bank of America upgraded the stock to “Buy” rating in Friday, January 15 report. The company was upgraded on Tuesday, October 27 by HSBC. The rating was downgraded by Exane on Thursday, August 6 to “Outperform”. The stock of Shire PLC (ADR) (NASDAQ:SHPG) has “Overweight” rating given on Friday, May 20 by JP Morgan. On Monday, October 26 the stock rating was maintained by RBC Capital Markets with “Sector Perform”.
According to Zacks Investment Research, “Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)”
More recent Shire PLC (ADR) (NASDAQ:SHPG) news were published by: Businessfinancenews.com which released: “Shire PLC (ADR) Future Now Rests On Xiidra” on July 12, 2016. Also Businessfinancenews.com published the news titled: “Shire PLC (ADR): Geared up to Inflate Drug Assortment” on June 21, 2016. Businessfinancenews.com‘s news article titled: “Shire Goes Deeper into Hemophilia Segment” with publication date: August 01, 2016 was also an interesting one.
SHPG Company Profile
Shire plc, incorporated on January 28, 2008, is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.